EnsiliTech® Showcases Breakthrough Biopreservation Technology as Royal Society of Chemistry Change Maker
Bristol, 17 June 2025 – EnsiliTech, a biotechnology company addressing the global challenge of cold chain dependency, was featured as a Deep Tech Change Maker by the Royal Society of Chemistry (RSC) at ChemUK 2025, the UK’s leading chemical and laboratory science exhibition.
The RSC’s Change Makers event, entitled "Shining a Light on Deep Tech Chemistry and the Innovation Journey", brought together chemistry-led startups, mentors, advisors, and impact investors to support and accelerate entrepreneurship in deep tech. As one of the featured ventures, EnsiliTech’s co-founder and CEO, Dr Asel Sartbaeva, presented the company’s Ensilication® technology — a patented method that uses silica to stabilise temperature-sensitive biologics such as vaccines, enzymes, and therapeutic proteins, allowing them to be stored and transported without refrigeration.
The event not only showcased groundbreaking innovations but also facilitated discussion on the startup journey, highlighting common challenges and opportunities in translating fundamental chemistry into commercial impact.
To accompany the event, a dedicated case study on EnsiliTech was published by the RSC, exploring the company’s evolution from academic research to scalable deep tech innovation. The case study highlights the scientific foundations of ensilication, its potential to revolutionise pharmaceutical supply chains, and role in supporting more resilient and equitable global healthcare.
🔗 Read the full case study:
https://changemakers.rsc.org/rsc-site/content/Case-studies/Deep-tech-case-studies.aspx
“Being recognised as a Change Maker by the RSC is a strong endorsement of our mission,” said Dr Asel Sartbaeva, co-founder and CEO of EnsiliTech. “We are proud to be part of a movement using chemistry to drive meaningful, scalable impact — ensuring life-saving medicines can reach those who need them, regardless of geography or infrastructure.”
EnsiliTech’s participation in the Change Makers event underscores the importance of deep tech solutions in tackling systemic challenges across healthcare and logistics. The company’s inclusion reflects the growing recognition of chemistry-driven innovation as a catalyst for real-world change.
About EnsiliTech
EnsiliTech is a pioneering biotechnology company dedicated to enhancing the stability and accessibility of biopharmaceuticals through its proprietary Ensilication technology. EnsiliTech is a Bristol-based startup, which spun out from the University of Bath in July 2022. In December 2022, EnsiliTech had finalised a first, oversubscribed, pre-seed investment round of £1.2M/$1.5M. This consisted of an Innovate UK grant and private investment from Science Angels Syndicate, Fink Family Office, QantX, and angels.
For further information please visit www.ensilitech.com.